Understanding how specific genes affect pancreatic cancer
Investigating the role of FOXA1/2 and HNF4⍺ in Pancreatic ductal adenocarcinoma
This study is looking at how certain proteins affect a type of aggressive pancreatic cancer called PDAC, to help find better ways to treat patients and improve their outcomes.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10903161 on NIH RePORTER |
What this research studies
This research investigates the role of specific transcription factors, FOXA1, FOXA2, and HNF4⍺, in pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. By analyzing the differences between two subtypes of PDAC, the classical and basal, the study aims to uncover how these factors influence tumor behavior and patient responses to treatment. The research employs integrated genomic, transcriptomic, and proteomic analyses to identify potential biomarkers and therapeutic targets that could improve patient outcomes. Ultimately, the goal is to enhance understanding of the disease and develop more effective treatments for patients diagnosed with PDAC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with the classical subtype.
Not a fit: Patients with other forms of pancreatic cancer or those who do not have pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that significantly improve survival rates for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in targeting specific transcription factors in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Orellana, Walter Alexander — University of Utah
- Study coordinator: Orellana, Walter Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.